[HTML][HTML] Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses

DM Morens, JK Taubenberger, AS Fauci - Cell host & microbe, 2023‏ - cell.com
Viruses that replicate in the human respiratory mucosa without infecting systemically,
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

N Chaudhary, D Weissman… - Nature reviews Drug …, 2021‏ - nature.com
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

Nirsevimab for prevention of hospitalizations due to RSV in infants

SB Drysdale, K Cathie, F Flamein, M Knuf… - … England Journal of …, 2023‏ - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …

Nirsevimab and hospitalization for RSV bronchiolitis

Z Assad, AS Romain, C Aupiais, M Shum… - … England Journal of …, 2024‏ - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody …

Nirsevimab for prevention of RSV in healthy late-preterm and term infants

LL Hammitt, R Dagan, Y Yuan… - … England Journal of …, 2022‏ - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV …

Mucosal vaccines—fortifying the frontiers

EC Lavelle, RW Ward - Nature Reviews Immunology, 2022‏ - nature.com
Mucosal vaccines offer the potential to trigger robust protective immune responses at the
predominant sites of pathogen infection. In principle, the induction of adaptive immunity at …

RSV prevention in all infants: which is the most preferable strategy?

S Esposito, B Abu Raya, E Baraldi, K Flanagan… - Frontiers in …, 2022‏ - frontiersin.org
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …

Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?

R Cohen, M Ashman, MK Taha, E Varon… - Infectious diseases …, 2021‏ - Elsevier
Since the beginning of the COVID-19 pandemic, reduced incidence of many viral and
bacterial infections has been reported in children: bronchiolitis, varicella, measles, pertussis …

Bronchiolitis

SR Dalziel, L Haskell, S O'Brien, ML Borland, AC Plint… - The Lancet, 2022‏ - thelancet.com
Viral bronchiolitis is the most common cause of admission to hospital for infants in high-
income countries. Respiratory syncytial virus accounts for 60–80% of bronchiolitis …

Prefusion F protein–based respiratory syncytial virus immunization in pregnancy

EAF Simões, KJ Center, ATN Tita… - … England Journal of …, 2022‏ - Mass Medical Soc
Background Respiratory syncytial virus (RSV), a major cause of illness and death in infants
worldwide, could be prevented by vaccination during pregnancy. The efficacy …